Molecular remission at T cell level in patients with rheumatoid arthritis

Jun Inamo, Katsuya Suzuki, Masaru Takeshita, Yasushi Kondo, Yuumi Okuzono, Keiko Koga, Yoshiaki Kassai, Maiko Takiguchi, Rina Kurisu, Akihiko Yoshimura, Tsutomu Takeuchi

研究成果: Article査読

4 被引用数 (Scopus)


While numerous disease-modifying anti-rheumatic drugs (DMARDs) have brought about a dramatic paradigm shift in the management of rheumatoid arthritis (RA), unmet needs remain, such as the small proportion of patients who achieve drug-free status. The aim of this study was to explore key molecules for remission at the T cell level, which are known to be deeply involved in RA pathogenesis, and investigate the disease course of patients who achieved molecular remission (MR). We enrolled a total of 46 patients with RA and 10 healthy controls (HCs). We performed gene expression profiling and selected remission signature genes in CD4+ T cells and CD8+ T cells from patients with RA using machine learning methods. In addition, we investigated the benefits of achieving MR on disease control. We identified 9 and 23 genes that were associated with clinical remission in CD4+ and CD8+ T cells, respectively. Principal component analysis (PCA) demonstrated that their expression profiling was similar to those in HCs. For the remission signature genes in CD4+ T cells, the PCA result was reproduced using a validation cohort, indicating the robustness of these genes. A trend toward better disease control was observed during 12 months of follow-up in patients treated with tocilizumab in deep MR compared with those in non-deep MR, although the difference was not significant. The current study will promote our understanding of the molecular mechanisms necessary to achieve deep remission during the management of RA.

ジャーナルScientific reports
出版ステータスPublished - 2021 12月

ASJC Scopus subject areas

  • 一般


「Molecular remission at T cell level in patients with rheumatoid arthritis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。